Literature DB >> 12228958

Update on motherisk updates. Seven years of questions and answers.

Adrienne Einarson1, Galina Portnoi, Gideon Koren.   

Abstract

QUESTION: Every month I read the Motherisk Updates in your journal and find them very helpful in counseling my patients on exposures during pregnancy and breastfeeding. I was wondering: what are the most common questions you receive from family physicians? ANSWER: Since the Motherisk Update began, we have received an increasing number of inquiries from family physicians across Canada. Most questions are about drug exposures. The three classes of drugs asked about most often are antidepressants, antiepileptics, and antihistamines.

Entities:  

Mesh:

Year:  2002        PMID: 12228958      PMCID: PMC2214092     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  12 in total

Review 1.  Drug therapy for breast-feeding women.

Authors:  S Ito
Journal:  N Engl J Med       Date:  2000-07-13       Impact factor: 91.245

2.  Fluoxetine/norfluoxetine concentrations in human milk.

Authors:  K J Burch; B G Wells
Journal:  Pediatrics       Date:  1992-04       Impact factor: 7.124

3.  Fluoxetine distribution in human milk.

Authors:  S B Duffull; E J Begg; K F Ilett
Journal:  J Clin Pharmacol       Date:  1996-11       Impact factor: 3.126

4.  First-trimester exposure to fluoxetine (prozac). Does it affect pregnancy outcome?

Authors:  G Koren
Journal:  Can Fam Physician       Date:  1996-01       Impact factor: 3.275

5.  Continuing drug therapy while breastfeeding. Part 2. Common misconceptions of physicians.

Authors:  G Koren; M Moretti; S Ito
Journal:  Can Fam Physician       Date:  1999-05       Impact factor: 3.275

6.  Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling.

Authors:  A Einarson; P Selby; G Koren
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

7.  Neurodevelopment of children exposed in utero to antidepressant drugs.

Authors:  I Nulman; J Rovet; D E Stewart; J Wolpin; H A Gardner; J G Theis; N Kulin; G Koren
Journal:  N Engl J Med       Date:  1997-01-23       Impact factor: 91.245

8.  Discontinuing antidepressants and benzodiazepines upon becoming pregnant. Beware of the risks of abrupt discontinuation.

Authors:  A Einarson; P Selby; G Koren
Journal:  Can Fam Physician       Date:  2001-03       Impact factor: 3.275

9.  Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)

Authors:  A Pastuszak; B Schick-Boschetto; C Zuber; M Feldkamp; M Pinelli; S Sihn; A Donnenfeld; M McCormack; M Leen-Mitchell; C Woodland
Journal:  JAMA       Date:  1993-05-05       Impact factor: 56.272

10.  Birth outcomes in pregnant women taking fluoxetine.

Authors:  C D Chambers; K A Johnson; L M Dick; R J Felix; K L Jones
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

View more
  3 in total

1.  Depression during Pregnancy : Overview of Clinical Factors.

Authors:  Heather A Bennett; Adrienne Einarson; Anna Taddio; Gideon Koren; Thomas R Einarson
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

2.  Health care providers' requests to Teratogen Information Services on medication use during pregnancy and lactation.

Authors:  Marie-Pierre Gendron; Brigitte Martin; Driss Oraichi; Anick Bérard
Journal:  Eur J Clin Pharmacol       Date:  2009-01-24       Impact factor: 2.953

3.  How physicians perceive and utilize information from a teratogen information service: the Motherisk Program.

Authors:  Adrienne Einarson; Andrew Park; Gideon Koren
Journal:  BMC Med Educ       Date:  2004-04-05       Impact factor: 2.463

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.